newsfilter
← Latest News
PR Newswire·

Aethlon Medical & North Immunology Announce Merger to Advance Novel IL-13 x IL-18 Bispecific Antibody for Atopic Dermatitis

AEMD
  • Aethlon Medical, Inc. entered a definitive all-stock merger agreement with North Immunology, Inc. to form a combined entity operating as North Immunology, Inc.
  • The combined company will trade on the Nasdaq Capital Market under the new ticker symbol NRTX.
  • An oversubscribed $180 million private placement was secured to fund the combined company's operations into the second half of 2028.
  • North Immunology's lead program, NOR-101, is a half-life extended anti-IL-13 x IL-18 bispecific antibody designed to inhibit both type 2 & non-type 2 inflammation for atopic dermatitis.
  • The Phase 1a study of NOR-101 is expected to begin in Q1 2027, with interim pharmacokinetic & safety data expected by mid-2027.
  • Phase 1b & Phase 2b top line data for NOR-101 are expected in 2028.
  • Pre-merger North Immunology stockholders are expected to own approximately 95.25% of the combined company, while pre-merger Aethlon stockholders will own approximately 4.75%.
  • Aethlon stockholders will receive contingent value rights (CVRs) for potential proceeds from future monetization of Aethlon's legacy Hemopurifier business.
  • The transaction is expected to close in Q1 2027, subject to stockholder approvals, SEC registration effectiveness, & Nasdaq listing approval.
  • The combined company will be led by North Immunology's existing management team & board of directors.